## Losmapimod Shows Tangible Clinical Benefits in FSHD Treatment: Fulcrum Therapeutics' Phase 2b Trial Data Published
Fulcrum Therapeutics has released Phase 2b clinical trial results for losmapimod in treating facioscapulohumeral muscular dystrophy (FSHD), with findings now published in *The Lancet Neurology*. The data reveal promising improvements across multiple clinical measures, advancing understanding of how this investigational therapy may address this rare progressive muscle disorder.
**Trial Design and Patient Demographics**
The ReDUX4 trial enrolled 80 participants with FSHD type 1 a
Fulcrum Therapeutics has released Phase 2b clinical trial results for losmapimod in treating facioscapulohumeral muscular dystrophy (FSHD), with findings now published in *The Lancet Neurology*. The data reveal promising improvements across multiple clinical measures, advancing understanding of how this investigational therapy may address this rare progressive muscle disorder.
**Trial Design and Patient Demographics**
The ReDUX4 trial enrolled 80 participants with FSHD type 1 a